ALX Oncology - UBS Global Biopharma Conference - ALX ONCOLOGY HOLDINGS INC
Financial Performance:
- The company reported being well-funded with cash reserves sufficient to sustain operations through mid-2028, following a $150 million capital raise in January.
- No specific revenue, EPS, or profit margin figures were disclosed, as the call focused exclusively on clinical pipeline updates and strategic milestones.
- The company is currently in a clinical development phase with no commercial products generating revenue yet.
Guidance and Future Outlook:
- ALX2004 (EGFR ADC) Phase 1 data is expected to be disclosed in early December, prior to the company's holiday party.
- EvorPRECEP (CD47) Phase 2 data in metastatic breast cancer is projected for the second half of 2027.
- Management anticipates being on the "doorstep" of two registrational studies within the next 12 months if current execution continues.
- Immediate focus shifts to expanding into second-line settings for both Head and Neck and Non-Small Cell Lung Cancer (NSCLC).
Business Segments and Product Lines:
- ALX2004 (EGFR ADC): An in-house developed antibody-drug conjugate designed to minimize on-target toxicities (specifically rash) by utilizing a unique epitope from metuzumab. The Phase 1 study enrollment has been adjusted to target 35+ patients, with a specific focus on 15+ patients at optimal doses in non-small cell lung cancer and head and neck cancer.
- EvorPRECEP (CD47): A CD47 inhibitor being evaluated in HER2-positive metastatic breast cancer. The ongoing Phase 2 (ASPEN-9) trial enrolls 120 HER2-positive patients to determine the optimal CD47 biomarker cutoff and assess efficacy in CD47-high vs. CD47-low subpopulations using an internal control design.
- Strategic Shift: Moving from broad immune-oncology approaches to highly targeted biomarker-driven indications (CD47-high and HER2-positive).
Market and Competitive Landscape:
- EGFR ADC Space: The EGFR target has historically failed due to skin toxicity (rash); competitors using cetuximab-derived constructs struggle with on-target effects. ALX distinguishes itself by using metuzumab to avoid wild-type EGFR on healthy skin.
- Head and Neck: Emerging competition from bispecifics (e.g., PETO) moving to frontline use; ALX targets the post-PETO or refractory population, leveraging a different epitope to address potential resistance mutations.
- NSCLC: Significant unmet need in squamous non-small cell lung cancer (wild-type), where other TROP2 ADCs (e.g., Adato DXd) have shown disappointing efficacy.
- Breast Cancer: Current standard of care in the second-line HER2+ setting shows poor outcomes (14-15% ORR); ALX aims to double this rate by targeting CD47-high patients.
Risks and Challenges:
- Toxicity Management: Despite design efforts to reduce rash, maintaining patient tolerability is critical; the goal is to reduce rash rates to under 15-20% (compared to >70% with cetuximab) to prevent dose discontinuation.
- Biomarker Validation: Uncertainty remains regarding the precise CD47 overexpression cutoff for commercialization and ensuring robust HER2 re-prognosis via fresh biopsies or ctDNA.
- Patient Population: Trials are recruiting heavily pre-treated patients (median 4th line in lung/head and neck), a difficult population with limited remaining therapeutic options.
- Clinical Execution: Risk of dose-limiting toxicities (DLTs) related to the payload at higher dose levels (4 mg/kg).
Management Commentary and Tone:
- Management (CEO Jason Letman) expressed high confidence and enthusiasm, describing the upcoming data as "inflection points" for the company.
- The tone was optimistic, emphasizing the technical novelty of the metuzumab epitope and the potential for "transformational" response rates (>30%) in late-line settings.
- Leadership highlighted the strategic advantage of avoiding skin toxicity and the unique ability to target mutations that may render other EGFR therapies ineffective.
Analyst Questions and Answers:
- Question on EGFR Toxicity: Analyst asked if the drug eliminates rash. Management clarified that while non-human primate data showed no rash, human data is awaited, but the goal is a significant reduction in rash to keep patients on drug.
- Question on Response Rates: Analyst questioned what constitutes a good response rate. Management stated double-digit rates are remarkable, >30% would be outstanding, and anything higher is transformative in a 4th-line setting.
- Question on Biomarker Strategy: Analyst queried the study design regarding CD47 cutoffs. Management explained the Phase 2 is designed to internally control for efficacy by comparing CD47-high vs. CD47-low patients within the HER2+ population to validate the biomarker for Phase 3.
- Question on Competition (PETO): Analyst asked about the impact of the emerging bispecific Peto. Management responded that ALX's different epitope (metuzumab vs. cetuximab) allows for efficacy in patients progressing on prior EGFR therapies.
Other Key Points:
- The ALX2004 study will prioritize non-small cell lung cancer and head and neck cancer enrollment based on observed therapeutic range efficacy.
- For the breast cancer trial, central confirmation of HER2 status is required, with ctDNA used as a backup for patients lacking fresh tissue; concordance rates for local vs. central testing are approximately 60-70%.
- Management noted that the EGFR ADC field is competitive but emphasized the specific opportunity in the squamous lung and post-bispecific head and neck niches.
- The company intends to disclose the ALX2004 data before the Christmas holiday period.
- Company
- ALX ONCOLOGY HOLDINGS INC
- Keywords
- ALX ONCOLOGY HOLDINGS INC